Journal of autoimmunityHumansSclerodermaSystemicRituximabFemale
Evaluation of the mycophenolate mofetil-rituximab combination in systemic sclerosis: a French retrospective multicenter study (MycRiSSc).
François Barde, Kevin Chevalier, Paul Decker, Matéo Merin, Amélie Nicolas, Alain Lescoat, Alban Deroux, Vincent Koether, Emmanuel Chatelus, Cyrille Coustal, Alexandre Maria, Martin Michaud, Grégory Pugnet, Anne Murarasu, Sébastien Riviere
Published: 202510.1016/j.jaut.2025.103492
Abstract
OBJECTIVES: Mycophenolate mofetil (MMF) and rituximab (RTX) are recommended as first-line therapies for skin and interstitial lung disease (ILD) involvement in systemic sclerosis (SSc). However, data on their combined use remain limited. This study e…
Preview only. Read the full abstract at the source